Pharmaceutical company VIVUS (Nasdaq: VVUS ) may have gained approval from the Food and Drug Administration for its weight loss drug, Qsymia, over the summer, but it just received the official rejection from the European Medicines Agency, or EMA. It became clear from preliminary information released in September that Qsymia -- which was going to be launched as Qsiva in the EU -- would be rejected by the EMA. Therefore, this news didn't come as a huge surprise to investors.
VIVUS stated that it will reapply for approval, but will this company lose a big market opportunity if it can't get its drug on the European market? Does this present an opportunity for its chief rival Arena Pharmaceuticals (Nasdaq: ARNA ) and its obesity drug, Belviq?
In the following video, health care analyst Max Macaluso discusses the reasons for Qsymia's EMA rejection and how this can impact the obesity drug market.
Editor's note: At 0:57, the speaker meant to say that Qsymia is made up of phentermine combined with topiramate. The Fool regrets the error.
With VIVUS facing this obstacle in the EU, investors should research Arena, too. The future looks bright for Arena, but there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.